You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

LAMISIL AT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lamisil At patents expire, and what generic alternatives are available?

Lamisil At is a drug marketed by Karo Hlthcare and is included in two NDAs.

The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lamisil At

A generic version of LAMISIL AT was approved as terbinafine hydrochloride by TARO on July 2nd, 2007.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LAMISIL AT?
  • What are the global sales for LAMISIL AT?
  • What is Average Wholesale Price for LAMISIL AT?
Drug patent expirations by year for LAMISIL AT
Drug Prices for LAMISIL AT

See drug prices for LAMISIL AT

Recent Clinical Trials for LAMISIL AT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oregon Health and Science UniversityEarly Phase 1
The Malassezia FoundationEarly Phase 1
Pak Emirates Military HospitalPhase 3

See all LAMISIL AT clinical trials

US Patents and Regulatory Information for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karo Hlthcare LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Karo Hlthcare LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 ⤷  Sign Up ⤷  Sign Up
Karo Hlthcare LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LAMISIL AT

See the table below for patents covering LAMISIL AT around the world.

Country Patent Number Title Estimated Expiration
South Africa 8005185 ⤷  Sign Up
South Africa 7804706 ⤷  Sign Up
Denmark 153470 ⤷  Sign Up
Czech Republic 283019 Topická farmaceutická kompozice, způsob její přípravy a způsob léčení fungálních infekcí (TOPIC PHARMACEUTICAL COMPOSITION) ⤷  Sign Up
Austria A602578 ⤷  Sign Up
Italy 1260710 COMPOSIZIONI FARMACEUTICHE CONTENENTI UN COMPOSTO ALLILAMMINICO QUALE PRINCIPIO ATTIVO. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LAMISIL AT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0024587 SPC/GB93/096 United Kingdom ⤷  Sign Up SPC/GB93/096, EXPIRES: 20050805
0024587 93C0136 Belgium ⤷  Sign Up PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.